Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (2)
  • ADC Antibody
    (1)
  • Antibody-Drug Conjugates (ADCs)
    (1)
  • DNA Alkylator/Crosslinker
    (1)
  • HER
    (1)
  • MDM-2/p53
    (1)
TargetMol | Tags By Application
  • ELISA
    (2)
  • FCM
    (2)
  • Functional assay
    (2)
TargetMol | Tags By ResearchField
  • Cancer
    (3)
Filter
Search Result
Results for "

jimt1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    3
    TargetMol | All_Pathways
  • Inhibitory Antibodies
    2
    TargetMol | Inhibitory_Antibodies
  • ADC/ADC Related
    2
    TargetMol | All_Pathways
PK11000
T445938275-34-2
PK11000 is a p53 targeting compound, has anti-tumor activities through activation of unstable p53.
  • $33
In Stock
Size
QTY
TargetMol | Citations Cited
Trastuzumab
T9912180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • $157
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Disitamab vedotin
RC-48, RC48, RC 48
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of Disitamab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
  • $347
In Stock
Size
QTY
TargetMol | Inhibitor Hot